Status:
UNKNOWN
Relationship Between Hypoxia and Endocrine Response in Human Breast Cancer
Lead Sponsor:
Fudan University
Conditions:
Breast Cancer
Hypoxia
Eligibility:
FEMALE
60-90 years
Brief Summary
The aim of our current study was to analyze whether 18F-labeled Fluoromisonidazole (1-(2-nitro-1-imidazolyl)- 2-hydroxy-3-fluoropropane \[18F-FMISO\]) PET/CT and expression of HIF-1-alpha could predic...
Detailed Description
Approximately 30% of ER-positive breast cancer will unfortunately display primary resistance to hormonal therapy, and some may develop acquired resistance to the therapy after initial treatment. Hypox...
Eligibility Criteria
Inclusion
- Postmenopausal female
- With primary invasive ER positive breast cancer pathologically approved by core needle biopsy
- The target lesion must be measurable and maximum diameter should be over 2cm.
- Require and accept Endocrine therapy
- Never treated with endocrine therapy before
- Patients must have an ECOG performance status of 0 to 2
- Leucocyte count must be ≥ 3.0\*10\^9/L and platelet count must be ≥ 40\*10\^9/L; AST/SGOT or ALT/AGPT must be \< 2 times the ULN; serum creatinine must be \< 2 times the ULN
Exclusion
- Patients with brain and liver metastasis
- Previous history of severe heart dysfunction (above Class III), infection, osteoporosis, bone related event or disease in endocrine system
- Combination of other anticancer therapy, with the exception of biphosphonate
Key Trial Info
Start Date :
March 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2014
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT01814449
Start Date
March 1 2012
End Date
May 1 2014
Last Update
March 20 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Hospital/ Institute, Fudan University
Shanghai, Shanghai Municipality, China, 200032